Nektar Therapeutics (NASDAQ:NKTR) had its price target lifted by investment analysts at Jefferies Group LLC to $25.00 in a report issued on Tuesday. The firm currently has a “positive” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective indicates a potential upside of 12.21% from the company’s previous close.

Several other research analysts have also weighed in on NKTR. Roth Capital set a $23.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 4th. Aegis boosted their price objective on shares of Nektar Therapeutics to $24.00 in a research note on Monday. BTIG Research assumed coverage on shares of Nektar Therapeutics in a research note on Friday, January 6th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Piper Jaffray Companies set a $25.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Nektar Therapeutics has a consensus rating of “Buy” and an average target price of $24.00.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) opened at 22.11 on Tuesday. The firm’s 50-day moving average is $13.78 and its 200-day moving average is $14.35. The company’s market cap is $3.40 billion. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $22.32.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The firm had revenue of $37.45 million for the quarter, compared to analyst estimates of $40.83 million. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.40) earnings per share. On average, analysts expect that Nektar Therapeutics will post ($1.35) EPS for the current fiscal year.

Your IP Address:

In other Nektar Therapeutics news, COO John Nicholson sold 75,000 shares of the stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $12.39, for a total transaction of $929,250.00. Following the transaction, the chief operating officer now owns 206,821 shares in the company, valued at approximately $2,562,512.19. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 87,500 shares of the stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $12.35, for a total transaction of $1,080,625.00. Following the transaction, the chief executive officer now owns 265,408 shares in the company, valued at approximately $3,277,788.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 465,689 shares of company stock worth $6,389,028. Company insiders own 6.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can increased its stake in shares of Nektar Therapeutics by 3.4% in the third quarter. Bank of Montreal Can now owns 6,395 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 208 shares during the period. Elkfork Partners LLC purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth $105,000. Strs Ohio increased its stake in shares of Nektar Therapeutics by 39.4% in the third quarter. Strs Ohio now owns 9,200 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 2,600 shares during the period. Gideon Capital Advisors Inc. purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth $145,000. Finally, Genesee Valley Trust Co. increased its stake in shares of Nektar Therapeutics by 0.4% in the third quarter. Genesee Valley Trust Co. now owns 12,189 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 54 shares during the period. Hedge funds and other institutional investors own 86.80% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.